ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

BMS to pay $475 million for Dragonfly’s IL-12 program

by Ryan Cross
August 21, 2020 | APPEARED IN VOLUME 98, ISSUE 32

 

Bristol Myers Squibb will pay $475 million to license an experimental cytokine drug from Dragonfly Therapeutics. The therapy, called DF6002, is an IL-12 immunoglobulin Fc fusion protein. IL-12 helps activate T cells and natural killer cells, and BMS suggests that DF6002 could induce inflammation around tumors. The therapy may help boost the efficacy of BMS’s cancer immunotherapy Opdivo. Dragonfly could earn additional milestone payments and up to 24% royalties if the drug is successful.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment